Nintedanib for Treating Idiopathic Pulmonary Fibrosis (TA379)

Technology Appraisal Guidance No. 379

Source: National Institute for Health and Care Excellence

1. Guidance

1.1 Nintedanib is recommended as an option for treating idiopathic pulmonary fibrosis, only if:

  • the person has a forced vital capacity (FVC) between 50% and 80% of predicted
  • the company provides nintedanib with the discount agreed in the patient access scheme and
  • treatment is stopped if disease progresses (a confirmed decline in percent predicted FVC of 10% or more) in any 12-month period.

1.2 People whose treatment with nintedanib is not recommended in this NICE guidance, but was started within the NHS before this guidance was published, should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.


The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at http://guidance.nice.org.uk/TA379

This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.

Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email: nice@nice.org.uk

Nintedanib for treating idiopathic pulmonary fibrosis

Issue Date: January 2016


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in